Working on the premise that establishing a causative, or more appropriately, inductive and facilitative association between CDH11 overexpression and cancer metastasis, is a vital step towards tagging it a targetable or actionable molecular driver of oncogenicity, and defining its therapeutic relevance in the effective management of advanced stage or metastatic breast cancer, we also provided preclinical evidence that the monospecific antibody targeting of CHD11 reduced the CD44hiCD24neg/lo population and suppressed the metastatic potential of breast cancer cells (Fig. 3). Here, CDH11 is linked to breast carcinoma.